Urticaria is a common allergic skin disease in clinical practice. The main manifestations of urticaria are wheal and pruritus. Some patients may be accompanied by angioedema, and the course of disease is more than 6 weeks, which is called chronic urticaria (CU). Urticaria vasculitis (UV) often presents with persistent wheal and itching symptoms, and histologically may present with mild leucocytocl
Conditions
Interventions
Urticarial vasculitis group:None
Sponsors
Huashan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Confirmed urticarial vasculitis: (a) Consistent with the symptoms of urticarial vasculitis, manifested as a wheal-like rash, which is not easy to completely resolve within 24 hours, and may be accompanied by itching or pain. (b) Histopathologically confirmed, consistent with the diagnosis of urticarial vasculitis. Urticarial vasculitis can be diagnosed if the above conditions are met at the same time. 2.Ages 18-75, no gender restrictions. 3.Use of at least one standard dose of second-generation antihistamines (sgAHs) for 2 weeks with poor efficacy (urticaria and pruritus occurring >= 3 days per week, with or without angioedema), or Omalizumab treatment non-tolerance or resistance 4.Patients with UV who have already been treated with upadacitinib or tofacitinib.
Exclusion criteria
Exclusion criteria: 1.Coexisting active or severe systemic diseases: such as uncontrolled diabetes, cardiovascular and cerebrovascular diseases, neurological disorders, severe liver and kidney dysfunction, severe coagulation system disorders, tumors, etc. 2.Combined with severe mental illness; 3.Pregnant and lactating women; 4.Infection, fever, or obvious signs of infection in blood routine results within two weeks; 5.Being allergic or desensitized to the investigational drug; 6.In the past 1 month, omalizumab, BTK kinase inhibitors and other biologics or non-JAK inhibitor small molecule drugs have been used. 7.The presence of other conditions that the clinical researchers believe should be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| UAS7 score;UCT scale;CU-Q2oL scale; | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse reaction; | — |
Countries
China
Contacts
Public Contacthui Tang
Huashan Hospital, Fudan University
Outcome results
None listed